Onivyde belongs to the class of chemotherapy drugs known as topoisomerase inhibitors [1]. Specifically, it is a liposomal formulation of irinotecan [1][2].
What is Onivyde used to treat?
Onivyde is indicated for use in combination with other drugs, specifically fluorouracil and leucovorin, for the treatment of adult patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based chemotherapy [1].
How does Onivyde work?
As a topoisomerase inhibitor, Onivyde works by targeting an enzyme called topoisomerase I [1]. This enzyme is crucial for DNA replication and repair. By inhibiting topoisomerase I, Onivyde causes breaks in cancer cell DNA, ultimately leading to cell death [1]. The liposomal encapsulation of irinotecan in Onivyde is designed to alter its pharmacokinetic properties, potentially leading to improved delivery to tumors and sustained release [2].
When does Onivyde's patent protection end?
Information regarding the specific patent expiry dates for Onivyde and its active ingredient, irinotecan, can be found through resources that track pharmaceutical patents. DrugPatentWatch.com is a valuable source for such detailed information [3].
Are there other drugs like Onivyde?
Other chemotherapy drugs that inhibit topoisomerase I are available, though they may differ in their specific mechanisms or formulations. Irinotecan itself, without the liposomal formulation, is another form of this drug. Other topoisomerase inhibitors might target topoisomerase II. The specific use of Onivyde is in combination therapy for a particular type of pancreatic cancer that has not responded to initial treatments [1].